Dr. Mace Rothenberg, MD
Mace L. Rothenberg, MD is a physician-executive with more than 30 years of experience across government, academia, and industry. Dr. Rothenberg recently retired from Pfizer where he served as Chief Medical Officer from 2019 to 2021. During this time, the company initiated, completed, and obtained emergency use authorization for its COVID-19 vaccine. Prior to that role, Mace led Clinical Development for Oncology at Pfizer from 2008 to 2018. Over that 10 year period, his organization developed and obtained regulatory approval for 11 new cancer medicines. Prior to joining Pfizer, Dr. Rothenberg was Professor of Medicine at Vanderbilt University and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center from 1998 to 2008. From 1991 to 1998, Mace was Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio and Executive Officer of the Southwest Oncology Group.
Dr. Rothenberg is board-certified in Internal Medicine and Medical Oncology and is a Fellow of the American College of Physicians and the American Society of Clinical Oncology.
Dr. Rothenberg received his BA magna cum laude from the University of Pennsylvania in 1978 and his MD from the New York University School of Medicine in 1982. He received his post-graduate training in Internal Medicine at Vanderbilt University and in Medical Oncology at the National Cancer Institute.